Please login to the form below
RA
This page shows the latest RA news and features for those working in and with pharma, biotech and healthcare.
The best work in healthcare communications shines at virtual Communiqué Awards
3.Excellence in Global Education Meetings/Stand-Alone Events. Sponsored by HEALTH UNLIMITED. Winner: LiBRA 2019: Looking Beyond the Joint in Rheumatoid Arthritis (RA): Is There a Missing Link in RA
Latest news
-
AbbVie’s JAK inhibitor Rinvoq approved in EU for rheumatoid arthritis
The pharma company has been pushing Rinvoq (upadacitinib) into the RA market, while its Boehringer Ingelheim-partnered drug Skyrizi (risankizumab) has been making headway in psoriasis. ... ICER also presented concerns over the long-term impact of
-
AbbVie scores FDA approval for arthritis treatment upadacitinib
AbbVie has been betting on its new products upadacitinib for RA and Skyrizi for psoriasis to combat Humira’s decline. ... If approved in Europe, AbbVie could begin to reclaim Humira’s lost ground in RA.
-
Gilead strikes $5.1bn deal to bolster ties with Galapagos
Filgotinib is however up against some tough competition in the market, from Pfizer’s blockbuster Xeljanz (tofacitinib) – already approved for RA, psoriatic arthritis and ulcerative colitis – as well as AbbVie’s ... well-regarded JAK1 inhibitor
-
Citryll snares €15m backing for its autoimmune disease NETs
New approach to tackling diseases such as lupus, RA. Dutch biotech Citryll has raised 15m ($17m) in first-round financing to help advance its new therapeutic approach to autoimmune diseases.
-
GSK pushes rheumatoid arthritis antibody into phase 3
Head-to-head trial necessary in crowded field. GlaxoSmithKline has opted to take its rheumatoid arthritis (RA) candidate otilimab into phase 3, despite mixed phase 2 results. ... Even combination treatment with multiple targeted drugs only achieves
More from news
Approximately 9 fully matching, plus 150 partially matching documents found.
Latest Intelligence
-
Drug launches to watch in 2019
The good news for the company is that it has not one but two potential blockbusters likely to gain approval in 2019: Upadacitinib (AbbVie) for RA and risankizumab (co-marketed with ... Likewise, upadacitinib will face competition in both RA and atopic
-
Deal Watch January 2018
Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China).
-
European CTR implementation advances ethical assessment of clinical trials
Timelines are becoming stricter with regard to the fact that compatibility with Regulatory Authority (RA) assessment must be ensured. ... Per the 2001/20/EC directive, assessment was independent from RA and this rule has created more flexibility for EC
-
Behavioural design - it's a no-brainer
Let's start with rheumatoid arthritis. Fatal medication errors relating to a disease-modifying medication for RA prompted an investigation into patient behaviour.
-
Deal Watch December 2015
Galapagos (NL). Gilead. Collaboration. licence. JAK1-selective inhibitor, filgotinib in phase II for RA and Crohn's disease .
More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.
Latest from PMHub
-
Lucid Group scoop a win and a high commendation at Communiqué 2020
Its programme – ‘LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?’ – won the category, with a high commendation going to ‘CLEAR HORIZONS –
-
Lucid Group are shortlisted in three categories for Communiqué 2020
LiBRA 2019: Looking beyond the joint in rheumatoid arthritis (RA): Is there a missing link in RA management?
-
WHITE PAPER: Patient nonadherence – the $637bn paradox
Geneva:. World Health Organisation; 2003. 7. Ward BW, Schiller JS, Goodman RA. ... Yugoslavia: discussion paper. J R Soc Med 1991; 84:288–291. 27. Boza RA, Milanes F, Slater V, Garrigo L, Rivera CE.
-
Infographic: Rheumatoid arthritis (RA)
An overview of the RA biologic patient. Our RA market snapshot offers an introduction to the real world patient data collected by our Therapy Watch RA study.
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
in the European RA market, where their convenient oral administration advantage may override cost considerations that would otherwise favour biosimilar uptake. ... The patient profile and unmet needs in RA. Profile of physicians prescribing JAKS.
More from PMHub
Approximately 2 fully matching, plus 25 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AZ strengthens Daiichi Sankyo partnership with new ADC deal
- Gut instincts lead Takeda to GI pipeline success
- New study identifies drugs that are safe to use in COVID-19 treatment
- How will the events and exhibitions industry change post-Coronavirus?
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- Eli Lilly begins COVID-19 prevention trial in nursing homes
- Porterhouse Medical Group joins imc group
- Biogen pays Denali $1bn upfront for Parkinson’s disease programme
- Tecentriq combo fails in advanced triple negative breast cancer
- Bristol-Myers Squibb’s revenues rise on Celgene acquisition
- Socially distanced strategising
- Artificial Intelligence in Digital Therapeutics
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- Virtual Engagement At Porterhouse: Reflections on the past few months
- A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
- July 2020: diversity and inclusion in clinical trials round-up
- COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
- Medical Device Clinical Trials 2020
- In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Quick links
Infographics
